Fibrostat 500 mg/5 ml (IM/IV Injection)

5 ml ampoule: ৳ 45.00 (1 x 5: ৳ 225.00)

Medicine Details

Category Details
Generic Tranexamic acid
Company Globe pharmaceuticals ltd
Also available as
Fibrostat 500 mg capsule

Title

  • Fibrostat

Categories

  • Medicine
  • Hemostatic Drugs
  • Anti-fibrinolytic Drugs

Description

  • Prophylaxis and therapy of hemoptysis, digestive hemorrhages, hemorrhagic syndromes in leukemia, cirrhosis and hemophilia, thrombocytopenic purpura, accidents during thrombolytic therapy and transfusion
  • Preparation of tranexamic acid with strong antifibrinolytic action, 10 times more active than conventional hemostatics
  • Low acute and chronic toxicity, well absorbed by oral route, excreted mainly by renal route
  • Usual adult dose: 500-1000 mg 3 times daily, children's dose based on body weight
  • Incompatible with solutions containing penicillins, antagonized by thrombolytic drugs, potential interaction with estrogen-containing drugs
  • Contraindicated in known hypersensitivity, thromboembolic disease, serious kidney failure, arterial and venous thrombosis, endocavitary hemorrhages
  • Rare side effects include sense of fatigue, conjunctival irritation, skin reddening, nausea, diarrhea, and rare cases of postural hypotension
  • Not to be administered during known and presumed pregnancy, passes into breast milk to low concentration unlikely to have antifibrinolytic effect in the infant
  • Precautions include use in hyperfibrinolysis cases, prophylactic treatment before operation, and caution in renal, cardiac, and hepatic dysfunctions
  • Storage at 15-30°C, away from light, in a dry place, and out of children's reach

Dimensions

  • N/A

ColorOptions

  • N/A

Functions

  • Prophylaxis and therapy of hemoptysis
  • Antihemorrhagic therapy during operations of any type and nature

Materials

  • Tranexamic acid (trans-4 aminomethyl-cyclohexanecarboxylic acid)

TechnicalSpecifications

  • Antifibrinolytic action 10 times more active than conventional hemostatics
  • Low acute and chronic toxicity, well absorbed by oral route, excreted mainly by renal route
  • Usual adult dose: 500-1000 mg 3 times daily, children's dose based on body weight

DesignElements

  • Preparation of tranexamic acid with strong antifibrinolytic action

UsabilityFeatures

  • Low acute and chronic toxicity, well absorbed by oral route, excreted mainly by renal route
  • Usual adult dose: 500-1000 mg 3 times daily, children's dose based on body weight

Warnings

  • Contraindicated in known hypersensitivity, thromboembolic disease, serious kidney failure, arterial and venous thrombosis, endocavitary hemorrhages
  • Precautions include use in hyperfibrinolysis cases, prophylactic treatment before operation, and caution in renal, cardiac, and hepatic dysfunctions

Storage

  • 15-30°C, away from light, in a dry place, and out of children's reach

Weight

  • N/A

AgeGroup

  • Adults
  • Children
  • Elderly patients

PowerSource

  • N/A

CareInstructions

  • Prophylactic treatment must begin 24 hours before the operation and continue until 3-4 days after it
  • Therapy of hemorrhages must be prolonged for at least 24 hours after manifestations have disappeared

SpecialFeatures

  • Strong antifibrinolytic action
  • Low acute and chronic toxicity
  • Well absorbed by oral route

OtherFeatures

  • Incompatible with solutions containing penicillins
  • Antagonized by thrombolytic drugs
  • Potential interaction with estrogen-containing drugs

Manufacturer

  • N/A

Brand

  • Fibrostat

ModelNumber

  • N/A

ReleaseDate

  • N/A

DiscontinuedDate

  • N/A

AdditionalFeatures

  • Antihemorrhagic action due to inhibition of plasminogen activation
  • Acute toxicity extremely low and chronic toxicity almost non-existent
  • Does not interfere with clotting processes

AssemblyRequired

  • N/A

Maintenance

  • N/A

LegalDisclaimer

  • Known individual hypersensitivity to the product
  • Not to be administered during known and presumed pregnancy

Industry or government certifications

  • N/A

Customer service

  • N/A

SafetyWarnings

  • Known individual hypersensitivity to the product

MedicalWarnings

  • Contraindicated in known hypersensitivity, thromboembolic disease, serious kidney failure, arterial and venous thrombosis, endocavitary hemorrhages

SpecialIngredients

  • Tranexamic acid (trans-4 aminomethyl-cyclohexanecarboxylic acid)

ReleaseType

  • N/A

AgeRecommendation

  • N/A

AwardsAndHonors

  • N/A

PatentInfo

  • N/A

Related Brands